At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 148 enrolled

Drug / intervention

placebo for adalimumab +2 moredrug

Likely dose

placebo for adalimumab 80 mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00645814

NCT00645814Phase 2Completed

Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Abbott·interventional·Posted Mar 28, 2008·Updated Mar 28, 2008

In Brief

A Phase 2 clinical trial evaluating placebo for adalimumab and adalimumab for Psoriasis. Completed, enrolled 148 participants.

Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsPsoriasis

Countries--

Collaborators--

Phase 2CompletedFinished

2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Enrollment StartMar 2003

Primary CompletionSep 2003

First PostedMar 2008

TodayJul 2026

First PostedMar 28, 2008

Enrollment StartMar 1, 2003

Primary CompletionSep 1, 2003

TodayJul 2, 2026

Enrollment to primary: 6 monthsPosted 18.3 years ago

placebo for adalimumabdrug

80 mg at Week 0 and 40 mg eow through Week 11

adalimumabdrug

80 mg at Week 0 and 40 mg eow through Week 11

adalimumabdrug

80 mg at Week 0 and 40 mg weekly through Week 11